

## **Global Cardiovascular Drugs Market Report and Forecast 2023-2031**

Market Report | 2023-04-20 | 147 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Cardiovascular Drugs Market Report and Forecast 2023-2031

Global Cardiovascular Drugs Market Outlook

The global cardiovascular drugs market size attained a value of USD 64.97 billion in 2022. The market is anticipated to grow at a CAGR of 2.66% during the forecast period of 2023-2031, driven by the rising prevalence of cardiovascular diseases across the globe. The global cardiovascular drugs market share is anticipated to achieve a value of USD 82.24 billion by 2031.

Key Trends in Global Cardiovascular Drugs Market

- Technological advancements in drug delivery systems: The development of innovative drug delivery systems, such as transdermal patches, inhalation devices, and injectable formulations, is expected to revolutionize the way cardiovascular drugs are administered. This will not only improve patient compliance but also enhance drug efficacy and reduce the risk of adverse events.
- Increasing use of combination therapies: Combination therapies, which involve the use of two or more drugs to treat cardiovascular diseases, are becoming increasingly popular. This is because they offer several advantages over monotherapy, such as improved efficacy, reduced risk of adverse events, and simplified treatment regimens.
- Rise in demand for personalized medicine: With the increasing availability of genetic testing and biomarker analysis, personalized medicine is becoming a key trend in the cardiovascular drugs market. By tailoring treatment to an individual's specific genetic and biomarker profile, healthcare providers can improve treatment outcomes and reduce the risk of adverse events.
- Emergence of gene therapy: Gene therapy, which involves the use of genetic material to treat or prevent diseases, is a rapidly evolving field. It has the potential to offer a cure for certain types of cardiovascular diseases and may become a key treatment option in the future.
- Growing focus on preventive care: With the increasing burden of cardiovascular diseases, there is a growing focus on preventive care. This includes lifestyle modifications such as exercise and healthy eating, as well as the use of drugs to reduce the risk of cardiovascular events in high-risk individuals.

Overall, these trends are expected to shape the cardiovascular drugs market from 2023 to 2031 and drive innovation in the

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott's-international.com](mailto:support@scott's-international.com)

[www.scott's-international.com](http://www.scott's-international.com)

development of new treatments and drug delivery systems.

#### Cardiovascular Drugs Market Segmentations

##### Market Breakup by Drug Class

- Antihypertensive Drugs
- Anticoagulants
- Antiplatelet Agents
- Antihyperlipidemic Drugs
- Antiarrhythmic Drugs
- Others

##### Market Breakup by Indications

- Hypertension
- Coronary artery disease
- Heart Failure
- Arrhythmias
- Dyslipidaemia
- Others

##### Market Breakup by Route of Administration

- Oral
- Parenteral
- Others

##### Market Segmentation by Drug Type

- Branded
- Generics

##### Market Breakup by End User

- Hospitals
- Homecare
- Specialty Clinics
- Others

##### Market Breakup by Distribution Channel

- Hospitals Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others

##### Market Segmentation by Region

###### North America

- United States of America
- Canada

###### Europe

- United Kingdom
- Germany
- France

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- []Italy
  - []Others
- Asia Pacific
- []China
  - []Japan
  - []India
  - []ASEAN
  - []Australia
  - []Others

- Latin America
- []Brazil
  - []Argentina
  - []Mexico
  - []Others

- Middle East and Africa
- []Saudi Arabia
  - []United Arab Emirates
  - []Nigeria
  - []South Africa
  - []Others

### Cardiovascular Drugs Market Analysis

The market is expected to experience significant growth in North America and Europe due to the high prevalence of cardiovascular diseases and a well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the highest growth rate due to a large population base, increasing disposable income, and a rise in awareness about cardiovascular diseases.

The market is expected to experience significant growth in North America and Europe due to the high prevalence of cardiovascular diseases and a well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the highest growth rate due to a large population base, increasing disposable income, and a rise in awareness about cardiovascular diseases.

Cardiovascular diseases, which are the leading cause of death globally, have become a major public health issue. As a result, there has been a significant increase in the demand for cardiovascular drugs. In conclusion, the cardiovascular drugs market is expected to witness significant growth from 2023 to 2031 due to an increase in the prevalence of cardiovascular diseases and a growing demand for effective treatment options. The market is expected to be driven by factors such as technological advancements, the development of innovative drugs, and a rise in awareness about cardiovascular diseases.

### Key Players in the Global Cardiovascular Drugs Market

The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- []F. Hoffmann-La Roche Ltd.
- []Fresenius Kabi AG
- []Bayer AG
- []Sun Pharmaceutical Industries Ltd.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- [ ] Novartis AG
- [ ] Mylan N.V.
- [ ] Teva Pharmaceutical Industries Ltd.
- [ ] Zydus Group
- [ ] Pfizer Inc.
- [ ] Lupin
- [ ] GSK Plc
- [ ] Glenmark Pharmaceuticals Inc.
- [ ] Capricor Therapeutics
- [ ] Zensun

## **Table of Contents:**

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cardiovascular Drugs Market Overview
  - 3.1 Global Cardiovascular Drugs Market Historical Value (2016-2022)
  - 3.2 Global Cardiovascular Drugs Market Forecast Value (2023-2031)
- 4 Global Cardiovascular Drugs Market Landscape
  - 4.1 Global Cardiovascular Drugs Company Landscape
    - 4.1.1 Analysis by Year of Establishment
    - 4.1.2 Analysis by Company Size
    - 4.1.3 Analysis by Region
  - 4.2 Global Cardiovascular Drugs Product Landscape
    - 4.2.1 Analysis by Drug Class
    - 4.2.2 Analysis by Indications
    - 4.2.3 Analysis by Route of Administration
    - 4.2.4 Analysis by End User
    - 4.2.5 Analysis by Distribution Channel
- 5 Global Cardiovascular Drugs Market Dynamics
  - 5.1 Market Drivers and Constraints
  - 5.2 SWOT Analysis
  - 5.3 Porter's Five Forces Model
  - 5.4 Key Demand Indicators
  - 5.5 Key Price Indicators
  - 5.6 Industry Events, Initiatives, and Trends
  - 5.7 Value Chain Analysis
- 6 Global Cardiovascular Drugs Market Segmentation
  - 6.1 Global Cardiovascular Drugs Market by Drug Class
    - 6.1.1 Market Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.2 Antihypertensive Drugs
- 6.1.3 Anticoagulants
- 6.1.4 Antiplatelet Agents
- 6.1.5 Antihyperlipidemic Drugs
- 6.1.6 Antiarrhythmic Drugs
- 6.1.7 Others
- 6.2 Global Cardiovascular Drugs Market by Indications
  - 6.2.1 Market Overview
  - 6.2.2 Hypertension
  - 6.2.3 Coronary artery disease
  - 6.2.4 Heart Failure
  - 6.2.5 Arrhythmias
  - 6.2.6 Dyslipidemia
  - 6.2.7 Others
- 6.3 Global Cardiovascular Drugs Market by Route of Administration
  - 6.3.1 Market Overview
  - 6.3.2 Oral
  - 6.3.3 Parenteral
  - 6.3.4 Others
- 6.4 Global Cardiovascular Drugs Market by Drug Type
  - 6.4.1 Market Overview
  - 6.4.2 Branded
  - 6.4.3 Generics
- 6.5 Global Cardiovascular Drugs Market by End User
  - 6.5.1 Market Overview
  - 6.5.2 Hospitals
  - 6.5.3 Homecare
  - 6.5.4 Specialty Clinics
  - 6.5.5 Others
- 6.6 Global Cardiovascular Drugs Market by Distribution Channel
  - 6.6.1 Market Overview
  - 6.6.2 Hospitals Pharmacy
  - 6.6.3 Online Pharmacy
  - 6.6.4 Retail Pharmacy
  - 6.6.5 Others
- 6.7 Global Cardiovascular Drugs Market by Region
  - 6.7.1 Market Overview
  - 6.7.2 North America
  - 6.7.3 Europe
  - 6.7.4 Asia Pacific
  - 6.7.5 Latin America
  - 6.7.6 Middle East and Africa
- 7 North America Cardiovascular Drugs Market
  - 7.1 Market Share by Country
  - 7.2 United States of America
  - 7.3 Canada
- 8 Europe Cardiovascular Drugs Market

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Cardiovascular Drugs Market
  - 9.1 Market Share by Country
  - 9.2 China
  - 9.3 Japan
  - 9.4 India
  - 9.5 ASEAN
  - 9.6 Australia
  - 9.7 Others
- 10 Latin America Cardiovascular Drugs Market
  - 10.1 Market Share by Country
  - 10.2 Brazil
  - 10.3 Argentina
  - 10.4 Mexico
  - 10.5 Others
- 11 Middle East and Africa Cardiovascular Drugs Market
  - 11.1 Market Share by Country
  - 11.2 Saudi Arabia
  - 11.3 United Arab Emirates
  - 11.4 Nigeria
  - 11.5 South Africa
  - 11.6 Others
- 12 Patent Analysis
  - 12.1 Analysis by Type of Patent
  - 12.2 Analysis by Publication year
  - 12.3 Analysis by Issuing Authority
  - 12.4 Analysis by Patent Age
  - 12.5 Analysis by CPC Analysis
  - 12.6 Analysis by Patent Valuation
  - 12.7 Analysis by Key Players
- 13 Grants Analysis
  - 13.1 Analysis by year
  - 13.2 Analysis by Amount Awarded
  - 13.3 Analysis by Issuing Authority
  - 13.4 Analysis by Grant Application
  - 13.5 Analysis by Funding Institute
  - 13.6 Analysis by NIH Departments
  - 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
  - 14.1 Analysis by Funding Instances
  - 14.2 Analysis by Type of Funding
  - 14.3 Analysis by Funding Amount

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
  - 15.1 Analysis by Partnership Instances
  - 15.2 Analysis by Type of Partnership
  - 15.3 Analysis by Leading Players
  - 15.4 Analysis by Geography
- 16 Regulatory Framework
  - 16.1 Regulatory Overview
    - 16.1.1 US FDA
    - 16.1.2 EU EMA
    - 16.1.3 INDIA CDSCO
    - 16.1.4 JAPAN PMDA
    - 16.1.5 Others
- 17 Supplier Landscape
  - 17.1 F. Hoffmann-La Roche Ltd.
    - 17.1.1 Financial Analysis
    - 17.1.2 Product Portfolio
    - 17.1.3 Demographic Reach and Achievements
    - 17.1.4 Mergers and Acquisitions
    - 17.1.5 Certifications
  - 17.2 Fresenius Kabi AG
    - 17.2.1 Financial Analysis
    - 17.2.2 Product Portfolio
    - 17.2.3 Demographic Reach and Achievements
    - 17.2.4 Mergers and Acquisitions
    - 17.2.5 Certifications
  - 17.3 Bayer AG
    - 17.3.1 Financial Analysis
    - 17.3.2 Product Portfolio
    - 17.3.3 Demographic Reach and Achievements
    - 17.3.4 Mergers and Acquisitions
    - 17.3.5 Certifications
  - 17.4 Sun Pharmaceutical Industries Ltd.
    - 17.4.1 Financial Analysis
    - 17.4.2 Product Portfolio
    - 17.4.3 Demographic Reach and Achievements
    - 17.4.4 Mergers and Acquisitions
    - 17.4.5 Certifications
  - 17.5 Novartis AG
    - 17.5.1 Financial Analysis
    - 17.5.2 Product Portfolio
    - 17.5.3 Demographic Reach and Achievements
    - 17.5.4 Mergers and Acquisitions
    - 17.5.5 Certifications
  - 17.6 Mylan N.V.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Teva Pharmaceutical Industries Ltd.
  - 17.7.1 Financial Analysis
  - 17.7.2 Product Portfolio
  - 17.7.3 Demographic Reach and Achievements
  - 17.7.4 Mergers and Acquisitions
  - 17.7.5 Certifications
- 17.8 Zydus Group
  - 17.8.1 Financial Analysis
  - 17.8.2 Product Portfolio
  - 17.8.3 Demographic Reach and Achievements
  - 17.8.4 Mergers and Acquisitions
  - 17.8.5 Certifications
- 17.9 Pfizer Inc.
  - 17.9.1 Financial Analysis
  - 17.9.2 Product Portfolio
  - 17.9.3 Demographic Reach and Achievements
  - 17.9.4 Mergers and Acquisitions
  - 17.9.5 Certifications
- 17.10 Lupin
  - 17.10.1 Financial Analysis
  - 17.10.2 Product Portfolio
  - 17.10.3 Demographic Reach and Achievements
  - 17.10.4 Mergers and Acquisitions
  - 17.10.5 Certifications
- 17.11 GSK Plc
  - 17.11.1 Financial Analysis
  - 17.11.2 Product Portfolio
  - 17.11.3 Demographic Reach and Achievements
  - 17.11.4 Mergers and Acquisitions
  - 17.11.5 Certifications
- 17.12 Glenmark Pharmaceuticals Inc.
  - 17.12.1 Financial Analysis
  - 17.12.2 Product Portfolio
  - 17.12.3 Demographic Reach and Achievements
  - 17.12.4 Mergers and Acquisitions
  - 17.12.5 Certifications
- 17.13 Capricor Therapeutics
  - 17.13.1 Financial Analysis
  - 17.13.2 Product Portfolio
  - 17.13.3 Demographic Reach and Achievements
  - 17.13.4 Mergers and Acquisitions
  - 17.13.5 Certifications

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.14 Zensun
  - 17.14.1 Financial Analysis
  - 17.14.2 Product Portfolio
  - 17.14.3 Demographic Reach and Achievements
  - 17.14.4 Mergers and Acquisitions
  - 17.14.5 Certifications
- 18 Global Cardiovascular Drugs Market - Distribution Model (Additional Insight)
  - 18.1 Overview
  - 18.2 Potential Distributors
  - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
  - 20.1 Very Small Companies
  - 20.2 Small Companies
  - 20.3 Mid-Sized Companies
  - 20.4 Large Companies
  - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
  - 21.1 Government Funded
  - 21.2 Private Insurance
  - 21.3 Out-of-Pocket

**Global Cardiovascular Drugs Market Report and Forecast 2023-2031**

Market Report | 2023-04-20 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-22"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com